Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 20

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
, Inc. would sublet office space located at 4700
Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000per month beginning January 14, 2022.
On April 26, 2024 the Company and BST agreed to amend that sublease agreement as follows:

The Company agreed that in addition to the base rent
of $5,000per month to be paid by the Company to BST the Company shall also reimburse BST for any and all shared expenses as such term
is defined within the original lease agreement by and between BST and CIF LaMesa LLP beginning January 1, 2024.

BST Partners is controlled by David Koos who serves
as the sole officer and director of Regen Biopharma, Inc.

$1,708lent to the Company by David Koos, the
Company’s sole Board Member and Officer, is due and payable at the demand of the holder and bears simple interest at a rate of15%
per annum.

$15,000lent to the Company by Zander Therapeutics,
Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of10% per annum.

$25,000lent to the Company by Zander Therapeutics,
Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of10% per annum.

$10,000lent to the Company by Zander Therapeutics,
Inc. is due and payable on October 4, 2025 and bears simple interest at a rate of10% per annum.

$4,700lent to the Company by Zander Therapeutics,
Inc. is due and payable on October 15 2025 and bears simple interest at a rate of10% per annum.

$4,500lent to the Company by Zander Therapeutics,
Inc. is due and payable on October 23 2025 and bears simple interest at a rate of10% per annum.

Zander Therapeutics, Inc. and the Company are under
common control.

During the quarter ended December 31, 2024 BST Partners
lent the Company $46,599

BST Partners and the Company are under common control.

  21  

Item 2. MANAGEMENT’ S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING
INFORMATION

Information